Bullish
$XERS @Jamiesutto Do not worry, there are plenty of things to be happy about and upcoming catalysts: - Commercial launch of Gvoke (next week). Let's see how sales traction - Data from the in-clinic portion of its Phase 2 study of post-bariatric hypoglycemia (PBH) before year-end - Data from the in-clinic portion of its Phase 2 study of exercise-induced hypoglycemia (EIH) before year-end - Completed enrollment in its Phase 2 study of hypoglycemia-associated autonomic failure (HAAF). Data from the 28-day treatment period of this study is expected by year-end - Pretty good amount of cash available (116M$) - Enough for 1 full year (not considering upcoming Gvoke revenues) A bit disappointed however by the late launch of the Gvoke HypoPen... GLTA longs. This quarter is where Xeris begins to demonstrate its potential
  • 3
  • 1